A phase I and pharmacokinetic study of indisulam in combination with carboplatin

British Journal of Cancer

Volumn 96, Issue 4, 2007, Pages 559-566

  Dittrich, C ^a,d   Zandvliet, A S ^b   Gneist, M ^a   Huitema, A D R ^b   King, A A J ^c   Wanders, J ^c  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c EISAI CO LTD   (Japan)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Carboplatin; Indisulam; Pharmacokinetics; Phase I

Indexed keywords

CARBOPLATIN; INDISULAM;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG INFUSION; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLATULENCE; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SARCOMA; SULFONAMIDES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33847182737     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603606     Document Type: Article

References (30)

1. Abd-Allah AR, Al-Majed AA, Al-Yahya AA, Fouda SI, Al-Shabana OA (2005) -carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol 79: 406-413
2. Beal SL, Boeckman AJ, Sheiner LB (1988) NONMEM User's Guides. San Francisco, CA: University of California at San Francisco
3. Belani CP, Aisner J, Hiponia D, Ramanathan R (1996) Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. Semin Oncol 23(Suppl 12): 19-21
4. Beumer JH, Rosing H, Hillebrand MJ, Nan-Offeringa LG, Foley K, Yule SM, Heck AJ, Schellens JH, Beijnen JH (2004) Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1, 4-benzene disulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 18: 2839-2848
5. Bunn Jr PA, Van Zandwijk N, Pastorino U, Aisner J, Alberto P, Arriagada R, Carney D, Cornis R, Dittrich C, Gatzemeier U, Ginsberg R, Greco FA, Hansen HH, Harper P, Henriksson R, Huber H, Klener P, LeChevalier T, Lewensohn R, Murray N, Niederle N, Postmus P, Rosell R, Scagliotti G, Sculier JP, Splinter T, Stahel R, Symann M, Thatcher N, Tonato M, Turrisi A (1994) First Euro-American Forum on lung cancer treatment of the European School of Oncology. Eur J Cancer 30A: 710-713
6. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140-147
7. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
8. Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH (2000) Patterns of practice survey for non-small cell lung carcinoma in the US. Cancer 88: 1336-1346
9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
10. Diskin CJ (2006) More on case 7-2006. N Engl J Med 355: 1502-1503
11. Ekhart C, deJonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH (2006) Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 12: 6502-6508
12. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, Narita N, Saijo N, Nishio K (2001) Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs 19: 219-227
13. Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH (2000) Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 67: 621-630
14. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy P, Lewis M, De Vore III RF (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14: 2054-2060
15. Kolarić K, Vukas D (1991) Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol 27: 409-412
16. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer; a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870
17. Martin M, Diaz-Rubio E, Casado A, Santabárbara P, López Vega JM, Adrover E, Lenaz L (1992) Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 10: 433-437
18. Muggia FM, Vafai D, Natale R, Israel V, Zaretsky S, McRae A, Rogers M, Jeffers S (1995) Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin Oncol 22(Suppl 9): 63-66
19. O'Brien MER, Talbot DC, Smith IE (1993) Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11: 2112-2117
20. Oda Y, Owa T, Sato T, Boucher B, Daniels S, Yamanaka H, Shinohara Y, Yokoi A, Kuromitsu J, Nagasu T (2003) Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 75: 2159-2165
21. Owa T, Ozawa Y, Yokoi A, Nagasu T, Renshaw FG, Yule M (2004) Identification of response marker genes of the anti-tumour sulfonamide indisulam (E7070). Eur J Cancer Suppl 2: 128, abstract no. 427
22. Ozawa Y, Owa T, Yokoi A, Yoshimatsu K, Asada M (2004) The combination of indisulam (E7070) with cisplatin, oxaliplatin and 5-fluorouracil are synergistic in vitro and in vivo. Eur J Cancer Suppl 2: 126, abstract no. 420
23. Raymond E, ten Bokkel Huinink WW, Taieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH (2002) Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20: 3508-3521
24. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, for the Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98
25. Shen M, Schilder RJ, Obasaju C, Gallo JM (2002) Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol 50: 243-250
26. Talbot D, Norbury C, Slade M, von Pawel J, Bosquee L, Ellis PA, Gatzemeier U, Ravic M (2002) A phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. Proc Am Soc Clin Oncol 21: 327a, abstract no. 1306
27. van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20: 4065-4073
28. van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351: 777-781
29. Wiltshaw E, Smales E, Gallagher CJ, Staffurth J (1987) Carboplatin (paraplatin) in ovarian cancer. Anticancer Drug Res 9: 3-8
30. Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD (2006) A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. J Pharmacokinet Pharmacodyn 33: 543-570